Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepastem
- Development stage
- Phase 2
- Lead developer
- Cellaion
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HepaStem is an allogeneic cell therapy composed of human heterologous liver progenitor cells (HHALPC), which are derived from healthy donated human livers. Developed by Promethera Biosciences (and subsequently Cellaïon), the therapy is designed to treat severe liver diseases including acute-on-chronic liver failure (ACLF), non-alcoholic steatohepatitis (NASH), and urea cycle disorders (UCD). HepaStem works through a multi-modal mechanism of action, primarily exerting anti-inflammatory and anti-fibrotic effects to reduce liver inflammation and promote tissue regeneration. It is administered via intravenous infusion and has been granted Orphan Drug Designation in the US and Europe for certain indications.
- Brand names
- HepaStem
- Other names
- Human Heterologous Liver Progenitor Cells
Beyond the preview
Go deeper on hepastem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepastem.